Company Overview and News

0
Update on Eclipse Residential Mortgage Investment Corporation

2018-06-07 globenewswire
TORONTO, June 07, 2018 (GLOBE NEWSWIRE) -- (TSX:ERM) Investors and investment advisors are invited to view the presentation that was provided at the recent annual general meeting of shareholders of Eclipse Residential Mortgage Investment Corporation (“Eclipse”). Eclipse is listed on the Toronto Stock Exchange under the ticker symbol ERM. Eclipse Investors may download the presentation on Brompton’s website by clicking on the following link:
ERM

0
Eclipse Residential Mortgage Investment Corporation Announces Results of Annual General Meeting

2018-05-31 globenewswire
TORONTO, May 31, 2018 (GLOBE NEWSWIRE) -- (TSX:ERM) Eclipse Residential Mortgage Investment Corporation (the “Corporation”) is pleased to announce that at an annual general meeting of holders (the “Shareholders”) of Common Shares in the capital of the Corporation that was held today, the nominees listed in the management information circular were elected as directors of the Corporation. Shareholders also approved the re-appointment of Ernst & Young LLP as auditor of the Corporation.
ERM

0
Eclipse Residential Mortgage Investment Corporation Announces Dividends

2018-04-23 globenewswire
TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- (TSX:ERM) Eclipse Residential Mortgage Investment Corporation (“Eclipse”) announces monthly dividends in the amount of $0.0625 per Common Share per month for record dates from April to June 2018.
ERM

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to TSX:ERM / Eclipse Residential Mort on message board site Silicon Investor.

GENI: GenesisIntermedia.com Inc Longer term short term day trades.
NWL: Newell Rubbermaid, Inc. Robert Zimmerman, Bob Dylan, Dylan
Qi cybermoney Longer-Term Market Trends
Bush-The Mastermind behind 9/11? Synopsys (SNPS) Steady long term growth
Thermo Electron (TMO) Buckeyu0027s Bottom Bounce Short Term Picks (CDN ONLY)